Back to results
US 2012/0059067 A1Published application
1-acetyl-5-hydroxyanthracene-9,10-dione for treatment of retinal disease
AssigneeCharlesson, LLC
InventorRafal A. Farjo
Life of this patent
Estimating the term…
Abstract
A composition may include a pharmaceutical carrier and an amount, therapeutically effective for the treatment of a retinal disease, of CLT-005 (1-acetyl-5-hydroxyanthracene-9,10-dione), wherein the retinal disease is characterized by at least one of inflammation, angiogenesis, or neovascularization, and wherein the composition is prepared for administration topically. The composition may be administered topically to a subject's eye.
Claims10
A composition comprising:
- a pharmaceutical carrier and an amount, therapeutically effective for the treatment of a retinal disease, of an agent having the formula:
- wherein the retinal disease is characterized by at least one of inflammation, angiogenesis, or neovascularization;
- and
- wherein the composition is prepared for administration topically.
1 more element
A method of treating a retinal disease in a subject, comprising:
- administering topically to the subject's eye a composition comprising a pharmaceutical carrier and an amount, therapeutically effective for the treatment of the retinal disease, of an agent having the formula:
- wherein the retinal disease is characterized by at least one of inflammation, angiogenesis, or neovascularization.
Dependencies are inferred from the claim text.